A new way to study brain dynamics, drugs, and disease

Michael Tadross is an assistant professor of Biomedical Engineering at Duke University, where he develops genetically encoded technologies to target clinical drugs to specific cell types in the brain. He applies these methods to mouse models of neuropsychiatric disease to determine which brain cell types are responsible for beneficial vs harmful effects, providing a roadmap for development of next-generation targeted therapeutics. He received his BS degree in electrical and computer engineering at Rutgers University, an MD/PhD degree in biomedical engineering at the Johns Hopkins School of Medicine, completed postdoctoral study in cellular neuroscience at Stanford University, and began his independent research program as a Fellow at the HHMI Janelia Research Campus.